Negative in Ames, in vitro chromosomal aberration and in vivo mouse micronucleus assays
“There was no evidence of mutagenicity or clastogenicity for atrasentan in in vitro bacteria reverse mutation and chromosomal aberration assays, or in an in vivo mouse micronucleus study.”
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Instead of genotoxicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
DRG histopathology
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reproductive & developmental
Rat and rabbit EFD: teratogenic at exposures below the MRHD
“In animal reproduction studies, oral administration of atrasentan to pregnant rats and rabbits throughout organogenesis at doses that were below the maximum recommended human dose (MRHD) based on area under the curve (AUC) caused teratogenic effects in rats and rabbits”
Dog telemetry: minimal QTc effect up to 51 times clinical Cmax
“In conscious dogs implanted with telemetry transmitters, atrasentan (≥10 mg/kg) showed minimal effects on heart rate-corrected QT interval at doses up to 51 times the maximal concentration achieved at the MRHD.”
“There was no evidence of mutagenicity or clastogenicity for atrasentan in in vitro bacteria reverse mutation and chromosomal aberration assays, or in an in vivo mouse micronucleus study.”
“There was no evidence of mutagenicity or clastogenicity for atrasentan in in vitro bacteria reverse mutation and chromosomal aberration assays, or in an in vivo mouse micronucleus study.”
“There was no evidence of mutagenicity or clastogenicity for atrasentan in in vitro bacteria reverse mutation and chromosomal aberration assays, or in an in vivo mouse micronucleus study.”
“Two long-term studies were conducted to evaluate the carcinogenicity of atrasentan: a 26-week study in Model 001178-T (hemizygous) CByB6F1-Tg(HRAS)2Jic mice and a 104-week study in Sprague Dawley rats.”
104-week Sprague Dawley rat and 26-week Tg(HRAS)2Jic (rasH2) mouse completed before the marketing application
“Two long-term studies were conducted to evaluate the carcinogenicity of atrasentan: a 26-week study in Model 001178-T (hemizygous) CByB6F1-Tg(HRAS)2Jic mice and a 104-week study in Sprague Dawley rats.”
“Atrasentan induced concentration-dependent inhibition of human ether-à-go-go-related gene tail current with an estimated 10% inhibitory concentration of approximately 2700-fold higher than maximum plasma concentration (Cmax) at the MRHD.”
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative